Experienced in Acquired Amegakaryocytic Thrombocytopenia

Hee K. Kim

Hwasun, KR 
Experienced in Acquired Amegakaryocytic Thrombocytopenia
Hwasun, KR 
OverviewLocationsClinical Research

Overview

Hee Kim practices in Hwasun, Republic of Korea. Ms. Kim is rated as an Experienced expert by MediFind in the treatment of Acquired Amegakaryocytic Thrombocytopenia. Her top areas of expertise are Thyroid Cancer, Papillary Thyroid Cancer, Medullary Thyroid Carcinoma, Thyroidectomy, and Endoscopy.

Her clinical research consists of co-authoring 324 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Acquired Amegakaryocytic Thrombocytopenia.

Gender
Female

Locations

Hwasun, Republic of Korea
Other Locations
Wondu, Republic of Korea
Cheongju-si, Republic of Korea
Seoul, Republic of Korea
Gwangju, Republic of Korea
Puch'on, Republic of Korea
Yuseong, Republic of Korea
Gyeonggi-do, Republic of Korea
Anseong, Republic of Korea
Gongju, Republic of Korea
Daejeon, Republic of Korea
Haeundae, Republic of Korea
Department Of Otorhinolaryngology Head And Neck Surgery, Cheonan, Republic of Korea
Songnam, Republic of Korea
Naju, Republic of Korea
Incheon, Republic of Korea
Busan, 602739, Republic of Korea
Gwang Ju, Republic of Korea
Daegu, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3

324 Total Publications

Experience of the Therapeutic Community Regarding Individuals With Alcohol Use Disorder: Phenomenological Study.
Experience of the Therapeutic Community Regarding Individuals With Alcohol Use Disorder: Phenomenological Study.
Journal: Journal of addictions nursing
Published: August 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Kim's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 103 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile